Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Teneligliptin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 known ✓ | P27487 | 20/20 | 0.98 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.98 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.98 |
| ▸ | HRH1 | P35367 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Teneligliptin SCHEMBL17065852 | 1.00 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17065851 | 1.00 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17270087 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL161778 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17270067 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL254082 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL16451097 | 0.99 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL14634647 | 0.98 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL2142591 | 0.98 | DPP4 (0.98) | DPP4DPP8DPP9PTGS2HRH1 | |
| Teneligliptin SCHEMBL17065854 | 0.97 | DPP4 (1.00) | DPP4DPP8DPP9PTGS2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | claimed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | claimed |
| EP-1930319-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-1308439-B1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | disclosed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | disclosed |
| US-7060722-B2 | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 5/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 5/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.